Natural Health Trends Corp. — FY2021 Form 10-K
Business context and reporting period. This annual report covers the fiscal year ended December 31, 2021; it does not provide a separate fourth-quarter financial summary. Natural Health Trends sells wellness, personal-care and related products through an international direct-selling and e-commerce model. Its business is highly concentrated: Hong Kong represented 77.8% of reported sales, and substantially all Hong Kong sales were from products delivered to members in China.
Key financial metrics
| Metric | FY2021 | FY2020 |
|---|---|---|
| Net sales | $60.0 million | $62.1 million |
| Gross profit / margin | $45.0 million / 75.0% | $45.1 million / 72.6% |
| Operating income / margin | $1.6 million / 2.6% | $0.7 million / 1.1% |
| Net income | $1.1 million | $0.8 million |
| Diluted EPS | $0.09 | $0.07 |
| Cash provided by operations | $1.0 million | $1.9 million |
- Sales fell 3% year over year. Hong Kong sales declined 5% to $46.7 million; sales outside Hong Kong increased 3%.
- Gross margin improved, primarily from lower logistics costs and fewer product promotions. Commissions were 42.6% of sales, versus 42.2% in 2020; SG&A declined 2% to $17.8 million.
- Cash and cash equivalents were $83.8 million at year-end, including $66.6 million of available-for-sale investments classified as cash equivalents. The company reported $68.8 million of working capital and a 3.79-to-1 current ratio. Cash and cash equivalents declined $8.5 million, primarily due to dividends.
- Operating cash flow was positive but modest and below the $9.1 million of dividends paid. Investing activities used $0.2 million. No borrowings are listed on the balance sheet; liabilities include $3.2 million of operating lease liabilities and substantial income-tax payables.
Material changes and unusual items
- Active members declined 12% to 45,760 from 52,230. Hong Kong membership fell to 33,510 from 41,130.
- Deferred revenue rose to $8.5 million from $3.1 million, primarily reflecting $6.5 million of unshipped orders and unredeemed product vouchers, compared with $1.0 million a year earlier. Management attributed the increase mainly to a voucher program launched in October 2020.
- Reported net income improved to $1.1 million from $0.8 million, while pretax income was nearly unchanged at $1.5 million. The income-tax provision decreased to $0.4 million from $0.6 million.
- The company paid quarterly dividends of $0.20 per share, totaling $9.1 million for the year. The board declared another $0.20-per-share dividend in February 2022; future dividends remain discretionary. The stock repurchase authorization had $21.9 million remaining at year-end.
Outlook, risks and contingencies
- Management expects near-term results may continue to be adversely affected; it provides no specific revenue or earnings guidance. COVID-19 restrictions, disrupted logistics and limits on in-person member events affected operations in 2021.
- China and Hong Kong exposure is a central risk. The Chinese direct-selling license application was withdrawn in 2019, and the company says it does not currently hold a China direct-selling license. It expects to reapply when circumstances permit but cannot predict approval or profitability. Regulatory scrutiny, the 100-day health-products campaign and related look-back review remain uncertainties.
- Other significant risks include member attrition, reliance on a limited number of product suppliers, concentration in three products that each generate at least 10% of revenue, currency movements, product and direct-selling regulation, and geopolitical and trade tensions.
- The company reported no legal proceedings. The SEC notified it in September 2021 that its investigation, begun in 2016, had concluded and that the SEC did not intend to recommend enforcement action. Management concluded internal controls over financial reporting were effective; the independent auditor did not audit or opine on their effectiveness.
- Marcum LLP issued an unqualified opinion on the financial statements. The auditor identified commissions expense and accrued commissions, including eWallet amounts, as a critical audit matter because of complex systems and management estimates.
Important facts for investors to verify
- Whether China-related sales and member activity recover, and how much reported Hong Kong revenue depends on deliveries to China.
- Whether deferred product orders and vouchers are fulfilled or redeemed, and how that affects future reported sales and cash flows.
- Whether member losses stabilize and whether the business can sustain profitability and operating cash generation while paying dividends.
- Supplier continuity for the three concentrated products, and any changes in Chinese licensing, regulatory enforcement or COVID-related restrictions.
- The amount and timing of income-tax payments, including the disclosed repatriation-tax liability, and the availability of cash subject to Chinese foreign-currency controls.